Investor Presentaiton

Opdivo (anti-PD1) Metastatic Trials Indication 1L HCC Phase III CheckMate -9DW - N = 732 Phase/Study # of Patients Opdivo + Yervoy Design sorafenib/lenvatinib Endpoints • Primary: OS Key secondary: ORR Status CT Identifier Projected data readout 2025 ll Bristol Myers Squibb Q3 2023 Results NCT04039607 Oncology Hematology Cell Therapy Immunology Cardiovascular • Opdivo (Arm A) 1L+ MSI High CRC Phase III CheckMate -8HW Opdivo + Yervoy (Arm B) Chemotherapy (Arm C) Primary: • PFS Arm B vs. A, all lines • PFS Arm B vs. C, first line Key secondary: ORR, OS N = 831 • Projected data readout 2025 NCT04008030 Not for Product Promotional Use 34

View entire presentation